Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALGSNASDAQ:CRISNASDAQ:FNCHNASDAQ:GRTS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALGSAligos Therapeutics$5.79+3.6%$5.88$3.76▼$46.80$35.40M2.76200,757 shs125,785 shsCRISCuris$2.09+2.5%$1.79$1.02▼$11.32$21.87M3.6570,783 shs19,181 shsFNCHFinch Therapeutics Group$13.70+5.4%$13.22$0.80▼$15.85$22.00M1.272,297 shs830 shsGRTSGritstone bio$0.35$0.03▼$3.17$3.50M0.497.01 million shs61.02 million shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALGSAligos Therapeutics+3.58%+2.84%+9.25%-65.45%-62.22%CRISCuris+2.45%+8.85%+12.37%-28.91%-81.29%FNCHFinch Therapeutics Group0.00%+0.74%+11.38%-13.24%+1,032.23%GRTSGritstone bio0.00%0.00%0.00%0.00%-95.98%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALGSAligos Therapeutics4.3646 of 5 stars3.54.00.04.82.81.70.6CRISCuris3.0511 of 5 stars3.55.00.00.02.80.01.3FNCHFinch Therapeutics GroupN/AN/AN/AN/AN/AN/AN/AN/AGRTSGritstone bioN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALGSAligos Therapeutics 3.00Buy$70.001,108.98% UpsideCRISCuris 3.00Buy$17.00713.40% UpsideFNCHFinch Therapeutics Group 0.00N/AN/AN/AGRTSGritstone bio 2.50Moderate Buy$2.17∞ UpsideCurrent Analyst Ratings BreakdownLatest FNCH, CRIS, ALGS, and GRTS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/19/2025CRISCurisHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy$17.003/31/2025ALGSAligos TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$70.00 ➝ $70.003/31/2025CRISCurisHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$20.00 ➝ $16.003/11/2025ALGSAligos TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$75.00 ➝ $70.00(Data available from 5/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALGSAligos Therapeutics$3.27M10.83N/AN/A$30.65 per share0.19CRISCuris$11.20M1.95N/AN/A$3.34 per share0.63FNCHFinch Therapeutics Group$110K200.02N/AN/A$14.25 per share0.96GRTSGritstone bio$496K0.00N/AN/A$0.54 per share0.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALGSAligos Therapeutics-$87.68M-$17.51N/AN/AN/A-1,283.19%-114.34%-64.58%8/5/2025 (Estimated)CRISCuris-$47.41M-$6.23N/AN/AN/A-443.35%-923.37%-78.35%8/7/2025 (Estimated)FNCHFinch Therapeutics Group-$74.75M-$8.82N/A∞N/AN/A-69.14%-26.92%N/AGRTSGritstone bio-$138.49M-$1.24N/AN/AN/A-910.50%-328.51%-82.53%N/ALatest FNCH, CRIS, ALGS, and GRTS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/6/2025Q1 2025ALGSAligos Therapeutics-$2.80-$2.11+$0.69-$2.11$0.33 million$0.31 million5/6/2025Q1 2025CRISCuris-$1.14-$1.25-$0.11-$1.25$2.37 million$2.38 million3/31/2025Q4 2024CRISCuris-$1.36-$1.25+$0.11-$1.25$2.04 million$2.70 million3/10/2025Q4 2024ALGSAligos Therapeutics-$2.63-$13.08-$10.45-$13.08$0.43 million$0.63 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALGSAligos TherapeuticsN/AN/AN/AN/AN/ACRISCurisN/AN/AN/AN/AN/AFNCHFinch Therapeutics GroupN/AN/AN/AN/AN/AGRTSGritstone bioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALGSAligos TherapeuticsN/A3.813.81CRISCurisN/A1.221.22FNCHFinch Therapeutics GroupN/A3.873.87GRTSGritstone bio1.832.542.54Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALGSAligos Therapeutics60.43%CRISCuris29.97%FNCHFinch Therapeutics Group21.77%GRTSGritstone bio48.46%Insider OwnershipCompanyInsider OwnershipALGSAligos Therapeutics8.75%CRISCuris5.45%FNCHFinch Therapeutics Group44.90%GRTSGritstone bio4.61%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALGSAligos Therapeutics906.11 million3.27 millionNo DataCRISCuris6010.46 million7.98 millionNo DataFNCHFinch Therapeutics Group1901.61 million885,000No DataGRTSGritstone bio190108.57 million111.84 millionOptionableFNCH, CRIS, ALGS, and GRTS HeadlinesRecent News About These CompaniesGritstone Bio sets sale of assets through Bankruptcy CourtDecember 13, 2024 | bizjournals.comGritstone Oncology Inc (GRTSQ)November 27, 2024 | investing.comGritstone bio, Inc. (GRTSQ)November 22, 2024 | finance.yahoo.comFirm Retention Summary: Gritstone bioNovember 20, 2024 | wsj.comGritstone bio trumpets first data for 'multivariant' COVID jabNovember 3, 2024 | pharmaphorum.comGritstone’s bankruptcy filing reveals biotech’s tough choicesOctober 14, 2024 | bizjournals.comGritstone Files for Bankruptcy in Effort to Save Clinical ResearchOctober 11, 2024 | biospace.comGritstone files for bankruptcy in hope of keeping cancer vaccine R&D afloatOctober 11, 2024 | fiercebiotech.comGritstone goes under after gruesome yearOctober 11, 2024 | thepharmaletter.comGritstone Oncology Pursues Restructuring Through Chapter 11October 11, 2024 | finance.yahoo.comWhy Gritstone Bio (GRTS) Stock Is Down 64% TodayOctober 11, 2024 | benzinga.comStock Slide and Strategic Moves: What’s Next for Gritstone Bio (GRTS)?October 10, 2024 | bovnews.comGritstone bio Takes Action to Preserve Value and Strengthen Capital StructureOctober 10, 2024 | businesswire.comGritstone stock craters 50% in wake of Phase 2 data, corporate updateOctober 3, 2024 | seekingalpha.comJones Trading Downgrades Gritstone bio (GRTS)October 3, 2024 | msn.comGritstone further eroded by cancer vaccine latestOctober 3, 2024 | thepharmaletter.comGritstone downgraded by Jones, B. Riley over cancer vaccine dataOctober 3, 2024 | seekingalpha.comCash-strapped Gritstone starts search for strategic alternatives as cancer vaccine data underwhelmOctober 1, 2024 | fiercebiotech.comKey Takeaways From Gritstone Bio Analyst RatingsOctober 1, 2024 | benzinga.comPenny Stock Gritstone Bio Hires Advisor To Evaluate Options, Analyst Downgrades Stock As Data 'Insufficient To Excite Many Investors'October 1, 2024 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeFNCH, CRIS, ALGS, and GRTS Company DescriptionsAligos Therapeutics NASDAQ:ALGS$5.79 +0.20 (+3.58%) Closing price 05/28/2025 04:00 PM EasternExtended Trading$5.77 -0.02 (-0.36%) As of 05/28/2025 07:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). The company also develops ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB); and ALG-125755, a siRNA drug candidate, which is in Phase I clinical trial for the treatment of CHB. In addition, it develops ALG-097558, which is in Phase 2 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH; license agreement with Emory University to provide hepatitis B virus capsid assembly modulator technology; license agreement with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; and research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.Curis NASDAQ:CRIS$2.09 +0.05 (+2.45%) Closing price 05/28/2025 04:00 PM EasternExtended Trading$2.06 -0.03 (-1.67%) As of 05/28/2025 07:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes. The company's pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; CA-170, an oral, small molecule antagonist designated as CA-170 that selectively targets PD-L1 and VISTA; and CA-327, an oral, small molecule, TIM3/PD-L1, which is a molecule antagonist of PD-L1 and TIM3. It has collaboration agreement with Genentech Inc., or Genentech and F. Hoffmann-La Roche Ltd, or Roche, for the commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway antagonist for the treatment of advanced basal cell carcinoma, or BCC; Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology; and also licensed four programs under the Aurigene collaboration, including emavusertib. Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts.Finch Therapeutics Group NASDAQ:FNCH$13.70 +0.70 (+5.38%) As of 05/27/2025 03:20 PM EasternFinch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524 for the prevention, diagnosis, theragnosis or treatment of diseases in humans, including ulcerative colitis; FIN-525 for the treatment of Crohn's disease; and other microbiome product candidates. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; and license agreements with Skysong Innovations LLC, OpenBiome, Arizona State University, and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Boston, Massachusetts.Gritstone bio NASDAQ:GRTSGritstone bio, Inc., a clinical-stage biotechnology company, engages in developing vaccine-based immunotherapy candidates against cancer and infectious diseases. Its primary product candidate is GRANITE, an individualized immunotherapy candidate, which is in Phase 2/3 clinical trials for the treatment of microsatellite stable colorectal cancers; and has completed Phase 1/2 clinical trials for treating solid tumors. The company is also developing SLATE, an off-the-shelf immunotherapy candidate, which is in Phase 2 clinical trials for the treatment of metastatic solid tumors. In addition, it develops CORAL, a COVID-19 vaccine program; and a therapeutic vaccine candidate that is in Phase 1 clinical trials designed to treat and cure human immunodeficiency virus (HIV) infection. Gritstone bio, Inc. has a strategic collaboration with bluebird bio, Inc.; collaboration agreement with Gilead Sciences, Inc.; and license agreement with Genevant Sciences GmbH. The company was formerly known as Gritstone Oncology, Inc. and changed its name to Gritstone bio, Inc. in May 2021. Gritstone bio, Inc. was incorporated in 2015 and is headquartered in Emeryville, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Toyota Supercharges Joby: $250M Capital Infusion Ignites Stock GameStop Buys Bitcoin: Smart Strategy or Big Mistake? Qualcomm Stock Turns South: 3 Entry Signals to Watch For D-Wave Quantum Stock: Are Advantage2 Gains Here to Stay? Meta's Institutional & Insider Data Fuels Bulls Despite Disparity Is Michael Burry Right Betting Against the Market Again? Amer Sports: The New ONON and DECK of Consumer Discretionary? BigBear.ai: Risky AI Stock or Defense Tech Opportunity? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
